Can Road-Side Tranexamic Acid Therapy Reduce Mortality and Blood Transfusions after Trauma? The CRASH Trial.

Can Road-Side Tranexamic Acid Therapy Reduce Mortality and Blood Transfusions after Trauma? The CRASH Trial.

0:00

JAIME MIRANDA, London School of Hygiene and Tropical Medicine, Peru An antifibrinolytic agent, tranexamic acid (commonly used to reduce bleeding during surgery) is being investigated as first-aid to c

Jaime Miranda

JAIME MIRANDA, London School of Hygiene and Tropical Medicine, Peru

An antifibrinolytic agent, tranexamic acid (commonly used to reduce bleeding during surgery) is being investigated as first-aid to cut mortality and the need for blood transfusion immediately after trauma or injury. The CRASH trial, still in its early phases in a worldwide adult population, aims to bring particular benefit to developing countries, many of which are blighted by trauma with few measures, if any, having been available up to now to reduce the death toll. In Lima, Peru, Jaime Miranda discussed his group’s ongoing investigation with Peter Goodwin.

Related Episodes

Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009

Oncology Times Broadcast News with the Audio Journal of Oncology – February 2009

Mary Eapen Peter Goodwin interviews more speakers from the 50th American Society of Hematology Annual Meeting, San Francisco, December 6-9, 2008 IN THIS EDITION: Greater Role for Umbilical Cord Blood

London School of Hygiene & Tropical Medicine Audio News

London School of Hygiene & Tropical Medicine Audio News

Andy Haines Peter Goodwin and Sarah Maxwell take part in the discussions held in London on the controversial role of the corporate sector in tackling the looming threat to global health of obesity aro

Oncology Times Broadcast News with the Audio Journal of Oncology

Oncology Times Broadcast News with the Audio Journal of Oncology

Francesco Zaja The exciting recent ASH conference reflected the vibrant mood of an America boldly tackling economic and political turmoil with post-presidential-election optimism. Peter Goodwin and Ge